A major factor complicating efforts to control the tuberculosis epidemic is the long duration of treatment required to successfully clear the infection. One reason that long courses of treatment are required may be the fact that mycobacterial cells arise during the course of infection that are less susceptible to antibiotics. Here we describe the paradigms of phenotypic drug tolerance and resistance as they apply to mycobacteria. We then discuss the mechanisms by which phenotypically drug-tolerant and -resistant cells arise both at a population level and in specialized subpopulations of cells that may be especially important in allowing the bacterium to survive in the face of treatment. These include general mechanisms that have been shown to alter the susceptibility of mycobacteria to antibiotics including growth arrest, efflux pump induction, and biofilm formation. In addition, we discuss emerging data from single-cell studies of mycobacteria that have identified unique ways in which specialized subpopulations of cells arise that vary in their frequency, in their susceptibility to drug, and in their stability over time. Citation: Aldridge BB, Keren I, Fortune SM. 2014. The spectrum of drug susceptibility in mycobacteria. Microbiol Spectrum 2(5):MGM2-0031-2013.
One of the major clinical challenges facing the tuberculosis (TB) field is the fact that long durations of treatment are required to fully clear infection. Patients with drugsusceptible TB are treated with 6 to 9 months of a multidrug regimen, while treatment of drug-resistant TB, which necessitates the use of less effective drugs, can take years. The lengths of the standard antibiotic regimens for TB have been empirically determined and have evolved as new TB drugs have been developed. Thus, initial regimens (with streptomycin [SM] or SM and 4-aminosalicylic acid [PAS]) were well over a year in duration; the long duration of therapy was deemed necessary based on patients' symptoms and long times until sputum conversion. The development of rifampin allowed the treatment course of uncomplicated, pulmonary TB to be shortened to 6 months. However, this is still substantially longer than the length of treatment required for other chronic infections; bacterial endocarditis, for example, which is considered difficult to clear, requires only 4 to 6 weeks of antibiotics.
What makes TB so difficult to treat? Several theories have been put forth, which we will broadly group into two categories. First, mycobacteria may be less easily cleared by antibiotics because of unique aspects of their physiology such as their slow growth rate and impermeable cell wall. We consider these to be generalized factors that describe the entire population of bacteria and, thus, can be studied at a population level. Second, an increasingly compelling explanation for the long duration of treatment is that within a mycobacterial population there are specialized subpopulations of cells that are extremely tolerant of antibiotics. These subpopulations of cells may be small, and their biology may be obscured in population-level analyses. Thus, identifying and studying the molecular biology of these subpopulations requires distinct experimental approaches. Importantly, however, there are conceptual similarities in the mechanisms underlying drug tolerance that act across entire populations or only within a subpopulation of cells. That is, drug tolerance typically reflects a few basic aspects of cell physiology-growth rate, metabolic state, cell wall composition, and permeability-that may change either globally or in subsets of cells.
DEFINITIONS
In a clinical diagnostic laboratory, Mycobacterium tuberculosis is tested for drug susceptibility, which is reported in binary terms: drug sensitive or drug resistant. These terms seem deceptively straightforward. Drug resistance is commonly understood to mean genetically encoded changes in the bacterium-either in the drug target or the drug activation pathway-that significantly reduce the activity of the given drug in a manner that cannot be overcome by simply increasing drug concentration. In mycobacteria, drug resistance is achieved by changes in the drug target or activating enzyme such that the drug can no longer act on its target or is not converted to its active form.
Drug susceptibility also seems self-evident. However, it is clear that drug susceptibility is more complicated than the binary definition from the clinical microbiology lab implies. First, there is a large body of literature demonstrating that for a given antibiotic, the efficacy of even a highly drug-susceptible strain of M. tuberculosis varies significantly according to bacterial growth conditions. This has been well demonstrated for environmental stressors such as hypoxia, nutrient limitation, and low pH, all of which are relevant conditions faced by M. tuberculosis in the infected host (1) (2) (3) (4) .
In addition, population-level measures of drug susceptibility obscure the fact that within a population of genetically identical cells, there are subpopulations of cells that can vary significantly in their drug susceptibility. The best known example of this is persister cells, which were identified as nongrowing and able to withstand drug concentrations many times higher than the MIC (5) (6) (7) (8) . However, more recent work in both model organisms and mycobacteria suggests that persister cells might be more accurately viewed as the end of a continuum of physiologic states, and thus drug susceptibilities, within a seemingly homogeneous population, arise through a variety of mechanisms.
Often, the convention in the field is to refer to these states of altered drug susceptibility as reflecting phenotypic drug tolerance. The term phenotypic is used to signify changes in drug activity that are temporary, dependent on a specific intrinsic or environmentally programmed physiologic state. Phenotypic is used in distinction to genetic effects, that is, effects that are encoded for on the chromosome.
We found it more difficult to rigorously define the term drug tolerance to distinguish it from drug resistance. The term drug tolerance can be used to denote instances where increased concentrations of drug are required to achieve the same effect as under the reference condition (typically logarithmic-phase growth). However, this definition covers many instances of what would be considered true drug resistance. For example, M. tuberculosis carrying genetic mutations in rpoB that confer what is considered to be genetic resistance to rifampin are killed by extremely high levels of rifampin exposure. Moreover, many studies do not elucidate the extent to which a change in mycobacterial susceptibility to drug can be overcome at high drug concentrations.
We therefore adopted an alternative definition of drug tolerance, which is the bacterial state that allows the bacterium to survive but not grow in the presence of drug, where changes in the bacterium that allow growth in the presence of drug with an increase in MIC would be considered drug resistance. Under this definition, drug tolerance becomes nearly synonymous with growth-arrested conditions. The temporary states that alter drug susceptibility but still allow growth (induction of efflux pump expression or variable KatG expression in some cells) will be considered phenotypic drug resistance. Importantly, the changes in drug susceptibility required to affect clinical outcome are poorly defined and likely to be different for each drug.
Here we explore mechanisms by which cells with phenotypic changes in drug susceptibility arise within a mycobacterial population ( Fig. 1 ). We include mechanisms identified through population-level studies, specifically growth arrest, efflux pump induction, and biofilm formation. We then consider the different mechanisms of altered drug susceptibility identified in single-cell studies. We anticipate that populationlevel studies will elucidate paths to phenotypic changes in drug susceptibility that will also be important to the durable survival of small subpopulations of mycobacterial cells under conditions where the bulk of the population is eliminated by drug. We expect that the importance of biologically distinct subpopulations will be better elucidated in future studies.
POPULATION-LEVEL DRUG TOLERANCE THROUGH GROWTH ARREST AND METABOLIC REMODELING
One of the pathognomonic features of TB is the chronic nature of the infection, as evidenced both by the slow progression of infection even in cases of active disease and, more clearly, by clinically latent infection. These clinical aspects of TB reflect significant metabolic changes in the organism in the host environment, the most obvious of which is growth slowing. The doubling time of M. tuberculosis (which is somewhere between 18 and 24 hours depending on the strain, under ideal growth conditions) slows dramatically in vivo, though there is some debate as to whether it fully stops (9, 10) .
The purpose of this article is not to comprehensively review the biology of dormancy in M. tuberculosis, as this has been reviewed in depth elsewhere. It is important to recognize, however, that growth slowing and the metabolic remodeling associated with growth arrest profoundly affect the susceptibility of M. tuberculosis to antibiotics. This has been shown most clearly in in vitro models of growth arrest that are thought to mimic specific aspects of the host environment including stationary phase, starvation, hypoxia, and low pH (5) (6) (7) (8) .
Nongrowing bacteria are no longer susceptible to the classes of antibiotics that specifically target growth machinery. Thus, cell wall biosynthesis inhibitors such as isoniazid are not active against nonreplicating organisms (1) . Likewise, M. tuberculosis that is growth arrested because of nutrient limitation is not susceptible to ciprofloxacin, an effect that cannot be overcome with increasing concentrations of drug (4, 6) .
However, even antibiotics that target processes essential for survival under all conditions, such as rifampin, display reduced efficacy against bacteria that are replicating only slowly or are in a low-activity metabolic state, though the relative change in drug efficacy is less profound than with the cell-wall-acting drugs. For example, in a study by de Steenwinkel et al., examining the time-kill kinetics of antimycobacterial drugs as a function of metabolic state, isoniazid showed rapid, concentration-dependent killing activity against replicating mycobacteria, while rifampin exhibited slow killing but was able to fully sterilize the mycobacterial culture (11) . In contrast, to achieve equivalent activity against a culture of mycobacteria characterized by a low metabolic state required a 64-fold increase in isoniazid concentration but only a 4-fold increase in rifampin concentration (11) .
The changes in growth rate and metabolic state do not, of course, imply reduced activity of every drug. As the examples of rifampin and isoniazid make clear, the effects are compound-and target-specific. Indeed, there are some antibiotics that have increased efficacy against dormant mycobacteria. The most obvious examples of this are the diarylquinolones, targeting ATP synthesis, which have increased activity against dormant mycobacteria (generated through hypoxia) as compared to actively growing cells (12) , and drugs that target the altered metabolic state specifically, such as metronidazole, which is active only under hypoxic conditions (13, 14) . Importantly, the path by which mycobacteria arrive in a growth-arrested state is likely to significantly impact the degree of drug tolerance. For example, subjecting mycobacteria to multiple stresses simultaneously (low oxygen, high carbon dioxide, low nutrient, low pH) produced cells that were more tolerant of rifampin than the cells reported by Wayne and Hayes (1, 15) to arise under hypoxic conditions alone.
While changes in growth rate and metabolic state are clearly important determinants of drug sensitivity in mycobacteria, recent work has demonstrated that other factors are also likely to play important roles in determining antibiotic efficacy. Advances in microscopy and single-cell biology have allowed investigators to ask questions about drug tolerance from new perspectives. Based on pioneering studies in other organisms, researchers have sought to identify drug-tolerant subpopulations of cells within an otherwise drug-susceptible population. These studies were initially driven by the identification of persister cells in model organisms. However, rather than simply identifying one mechanism by which drug-tolerant cells are generated, these studies have found multiple mechanisms by which mycobacterial populations generate cells of different drug susceptibilities. The characteristics of these subpopulations of cells differ in the degree of drug tolerance conferred and the frequency with which drug-tolerant cells arise. The data therefore suggest a spectrum of physiologic states within what is typically considered to be a homogeneous population. Below, we consider some major mechanisms by which these drug-tolerant states arise, beginning with high-frequency mechanisms and concluding with a discussion of persister cells, as the term has been classically used in the literature. Importantly, to date, many of these studies have been done in the model mycobacterium Mycobacterium smegmatis rather than M. tuberculosis, though as live cell imaging becomes more accessible in the biosafety level 3 environment, we expect these approaches to be applied to M. tuberculosis as well (16) (17) (18) (19) .
DRUG RESISTANCE THROUGH EFFLUX PUMP INDUCTION
The induction of multidrug-resistant efflux pumps is a well-defined mechanism by which bacterial cells lower their exposure to toxins and achieve phenotypic drug tolerance (20) . In Gram-negative bacteria, efflux pumps consist of multiple components spanning the periplasm to transport molecules across both the inner and outer membrane. Pseudomonas aeruginosa, a Gram-negative opportunistic pathogen, is a well-studied example of efflux pump-mediated drug resistance. P. aeruginosa is "intrinsically" resistant to many antibiotics including fluoroquinolones, chloramphenicol, tetracycline, and beta-lactams (21) (22) (23) . The cell wall of P. aeruginosa is relatively impermeable compared to other Gram-negative bacteria, and it was thought that this impermeability caused the relative drug tolerance. However, using a combination of theoretical and experimental evidence, Livermore and Davy (24) and Nikaido (25) showed that the timescale of drug permeation is on the order of seconds, casting doubt on this hypothesis. Instead, Li et al. (22) postulated that efflux pumps caused this apparent intrinsic resistance to a wide variety of molecules. They found that P. aeruginosa isolates actively efflux tetracycline, chloramphenical, norfloxacin, and beta-lactams, and highly drug-resistant isolates transport more drug. The MexAB-OprA efflux pump system had recently been described by Poole et al. using knockouts of the multicomponent pump to generate drugsensitive strains (26) . Li et al. found upregulation of these components in highly drug-resistant bacterial isolates (22) . Since then, multidrug efflux pumps have been implicated in drug resistance of many other Gramnegative pathogens including Escherichia coli, Salmonella enterica, Acinetobacter baumannii, Campylobacter jejuni, and Neisseria gonorrhoeae (reviewed in references 21 and 27).
Gram-positive bacteria express three classes of singlecomponent multidrug-resistant efflux pumps. Multidrugresistant efflux pumps have been implicated in drug resistance in pathogenic Gram-positives including Staphylococcus aureus and Streptococcus pneumoniae (21, 28) . For example, overexpression of NorA, a member of the major facilitation superfamily (MFS) of efflux pumps, has been identified in some clinical isolates of methicillinresistant S. aureus (MRSA) (21, (29) (30) (31) .
Both slow-and fast-growing mycobacterial species express several single-component drug efflux pumps (membranetransport.org) belonging to both the MFS and the ATP-binding cassette (ABC) superfamily. Reminiscent of the intrinsic drug tolerance of P. aeruginosa, it was first hypothesized that drug resistance in mycobacteria is caused by cell wall impermeability from the thick mycolic acid layer of mycobacteria (32) . However, again like P. aeruginosa, drug access occurs within minutes, suggesting that mycobacteria achieve drug tolerance through a combination of impermeability and active efflux (33, 34) .
The first transporter characterized in mycobacteria was LfrA, an MFS pump (35) . Takiff et al. found that M. smegmatis expressing LfrA-containing plasmids exhibited increased tolerance to fluoroquinolones and was more able to acquire genetic fluoroquinolone resistance (35) . Importantly, a single transporter does not target just one drug, but commonly is capable of effluxing several molecules. Therefore, expression of one type of pump can create resistance to multiple drugs in parallel. Srivastava et al. recently found that shortly after treatment of M. tuberculosis with ethambutol, resistance to both isoniazid and ethambutol emerges (36) . Cotreatment with reserpine, an efflux pump inhibitor, decreased the rate of isoniazid and ethambutol resistance.
Since this identification, increased expression of efflux pumps has been identified in drug-tolerant clinical isolates, suggesting that efflux pumps contribute to drug tolerance in a clinically meaningful way (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) . In addition, efflux pump expression has recently been shown to be induced in vivo (during macrophage infection), where it can contribute to rifampin and isoniazid resistance. Adams and colleagues showed efflux pump induction in Mycobacterium marinum and M. tuberculosis during macrophage infection (40) . The authors showed that almost 50% of M. marinum cells were tolerant of rifampin treatment 4 days post-infection. Sub-MIC levels of the efflux pump inhibitors verapamil and reserpine decreased the number of rifampin-resistant cells, providing a potential clinically applicable solution to treatment failure in TB.
Thus, host-or drug-induced stress may induce expression of efflux pumps that act to quickly lower the concentration of drug in cells, creating temporary states of drug resistance. Increasing attention is being drawn to the role of efflux pumps in virulence and survival during hostile host conditions in many pathogens including P. aeruginosa, C. jejuni, N. gonorrhoeae, and E. coli (reviewed in reference 21). Induction of multidrug resistance efflux pumps in pathogenic mycobacteria upon infection suggests that the virulence capacity and drug efficacy in individual cells may be connected by efflux pumps. Understanding the dynamics of drug efflux, molecular cross-talk and specificity among efflux pumps, and transporter expression and induction may be a critical step toward designing improved therapeutic regimens that include the use of efflux pump inhibitors. Inhibitors that target host cell efflux pumps may also increase the concentration of drug to which mycobacteria residing in protected niches are exposed, such as those recently found to reside in mesenchymal bone marrow stem cells (46) .
POPULATION-LEVEL CHANGES IN DRUG EFFICACY THROUGH BIOFILM FORMATION
Many species of bacteria form biofilms, creating an organized conglomerate of cells that are physically linked, usually by an extracellular matrix. Several bacterial biofilms have been studied extensively including those formed by P. aeruginosa, E. coli, Bacillus subtilis, and S. aureus. Biofilm provides distinct environments for different subpopulations, stratifying and physically organizing access to signaling molecules, metabolites, and stressors (28, (47) (48) (49) (50) . The biofilm lifestyle also induces changes to cell morphology, gene expression, and, of importance when considering drug activity, changes in growth rate, efflux pump expression, and metabolic state (28, 49, (51) (52) (53) (54) . Moreover, as discussed below, specialized subpopulations of cells including persister cells are generated at high rates under biofilm conditions. Consequently, bacteria in biofilms can be profoundly insensitive to drug-likely encompassing both phenotypically drug-tolerant and phenotypically drugresistant populations (28, (47) (48) (49) (50) .
Mycobacteria are well known for their waxy cell walls, which make them clump and be difficult to grow in liquid media without detergents. Without detergents and surfactants, mycobacteria form biofilms in liquid culture (pellicles) and on solid media (55) (56) (57) (58) (59) (60) . In vivo, extracellular mycobacteria form cords, which can be viewed as a type of biofilm, in the caseum of granulomas, and convex biofilms in extracellular regions inside of granulomas (61, 62) .
Unlike many biofilm-forming bacteria, mycobacteria do not excrete exopolysaccharides as an extracellular matrix to develop and maintain biofilms (63) . In an elegant series of experiments, Ojha and colleagues found that short-chain fatty acids in the mycobacterial mycolic acids are required for biofilm formation and that this process is regulated by GroEL1 (55) . In essence, changing the property of their waxy cell wall determines the biofilm structure. Biofilm formation is inhibited by disruption of mycolic acid synthesis by mutation of inhA or kasB, loss of GroEL1 function by infection with Bxb1 mycobacteriophage, or depletion of iron (55, 59, 64) . In vitro, Ojha et al. have observed enrichment of isoniazid and rifampin-tolerant M. tuberculosis in biofilms compared to biofilm-free culture conditions or biofilmdeficient mutant strains (64) .
The spatial localization and different cellular properties of drug-tolerant and drug-resistant mycobacteria in biofilms have yet to be characterized. Properties such as growth rate, permeability (correlating with mycolic acid composition), and drug efflux may be important determinants of drug efficacy that are supported by these three-dimensional structures. Live cell imaging in bioreactors and microfluidic devices may help us understand how biofilms are generated and how they contribute to the generation of protection of a significant subpopulation from antibiotic stress in these environments (53, 65) . Biofilm formation, structure, and relationship to immune stress tolerance in vivo also remain to be studied.
RAPID GENERATION OF DRUG-TOLERANT CELLS THROUGH ASYMMETRIC GROWTH
Slow growth is commonly cited as a determinant of drug tolerance (66-68), with nongrowing persisters at the extreme end of the spectrum. Aldridge et al. (16) have recently demonstrated that cell-to-cell variation in growth properties contributes to mycobacteria's variable response to drug treatment. They found that mycobacteria exhibit an asymmetric growth pattern, whereby cells elongate predominantly from their older pole ( Fig. 2A ). Because cells are polarized, each sister cell inherits a different pole. The daughter cell that inherits the older, faster-growing pole is born larger and elongates faster than its sister and is called an "accelerator." The sister inheriting the newer, slower-growing pole from the mother cell must convert this slow-growing pole into a fast-growing pole and is therefore called an "alternator." As growth poles mature, the cell size and growth rate also increase. Thus, the asymmetric growth of mycobacteria innately instills diversity in the growth rate and size of cells ( Fig. 2B and 2C ). This diversity arises in even very small populations, because each microcolony (seeded from a single cell) contains cells with growth poles of different ages.
The variation in growth rate between alternator and accelerator cells is modest (∼10%), yet the physiological differences between these cell types are enough to correlate with differences in drug effect. The faster-growing accelerator cells exhibit reduced survival in the face of treatment with cell wall-acting antibiotics (cycloserine, meropenem, and isoniazid) at minimal inhibitory con-centrations, whereas alternator cells are more susceptible to rifampin, an inhibitor of transcription (Fig. 2D) . Together, these findings suggest that subtle variations in growth characteristics translate into differences in drug tolerance at a single-cell level.
However, it is important to note that the spectrum of growth phenotypes is not sufficient to fully describe variation in drug response. Aldridge et al. (16) observed microcolony-to-microcolony variation in drug effect, notably in response to isoniazid and rifampin treatment. This variability suggests that there are additional semiheritable factors of drug tolerance.
HERITABLE DRUG TOLERANCE THROUGH VARIATION IN ENZYME CONCENTRATION
M. smegmatis cells capable of surviving sustained, high doses of isoniazid treatment have recently been characterized. By tracking M. smegmatis in a microfluidic device, Wakamoto and colleagues recently observed turnover of isoniazid-resistant mycobacteria (17) . These cells grow and divide, and a small proportion of their progeny continue to resist drug treatment. While the number of resistant cells remains relatively constant, there is a dynamic growth and death process underlying this apparent steady state. These single-cell observations are consistent with bulk measurements of replication (9) and mutation (69) of M. tuberculosis in latency in vivo.
Under high-dose treatment conditions, Wakamoto et al. (17) observed that sister cell pairs exhibited a correlated response to isoniazid treatment, suggesting that an epigenetic factor may play a key role in isoniazid resistance. Interestingly, the possible contribution of semi-heritable factors was also suggested by the microcolony-to-microcolony variation observed following MIC-level treatment with isoniazid (16) .
Isoniazid is delivered as a prodrug and relies on conversion to the active form by catalase-peroxidase, expressed by katG in mycobacteria. Because small (∼2fold) increases in katG induction produced significant (∼1,000-fold) increases in bacterial death, Wakamoto et al. (17) explored how variation in katG expression at a single-cell level contributed to isoniazid resistance. Using a KatG-fluorescent fusion, they were able to simultaneously measure the dynamics of katG expression, lineage, and response to isoniazid treatment. They observed a surprising pulsing of KatG (on the scale of ∼5 hours) and a correlation between katG expression and isoniazid susceptibility: that is, cells scored as katG positive were less capable of surviving isoniazid, scored by the ability to divide after the drug was removed. . Following division, the two sister cells exhibit different growth properties. The cell inheriting the growth pole (called an "accelerator") elongates faster and is born larger than its sister (called an "alternator"). (D) Distribution of differential drug susceptibility in accelerator and alternator cells in individual microcolonies. Using microfluidics, M. smegmatis microcolonies were challenged with MIC levels of antibiotics (meropenem and rifampicin shown here) and scored for survivors by their ability to elongate in recovery media. All figures were adapted from Aldridge et al. (16) . doi:10.1128/microbiolspec.MGM2-0031-2013.f2
PROLONGED DRUG TOLERANCE THROUGH THE FORMATION OF A PERSISTER CELL POPULATION
The idea that some cells are phenotypically drug tolerant was first raised by Joseph Bigger in 1944 (5). Bigger was not able to sterilize a culture of Staphylococcus using penicillin, explaining that "The only hypothesis which seems to explain the occurrence of a small number of survivors out of the millions of cocci originally present is that these differ from the majority of their fellows in that they are capable of surviving a concentration of penicillin which, in the time of action allowed, kills the others." Bigger named these surviving cells "persisters," meaning a small phenotypic variant in all bacterial populations that do not die in the presence of high doses of bactericidal drugs for long periods of time that are capable of killing the bulk of the population (Fig. 3A) . When the antibiotic is removed and the bacterial population is reestablished, the new population has a similar level of persisters, indicating that persisters are not genetic mutants but, rather, phenotypic variants (5, 70) .
Persisters have typically been observed by adding bactericidal drugs to a bacterial population and enumerating the number of surviving cells; a clear biphasic curve emerges, with the bulk of the population dying rapidly, while persisters die slowly or do not die at all (Fig. 3A) . The majority of research has concentrated on E. coli persisters, but persisters were also identified in many other bacterial species including P. aeruginosa, M. tuberculosis, S. enterica serovar Typhimurium, S. aureus, and Streptococcus mutans, and even in the fungal pathogen Candida albicans (6, (71) (72) (73) (74) (75) (76) .
High-Persistence (hip) Mutants
The importance of persisters was not immediately appreciated, and little research was done until the early 1980s, when Harris Moyed and coworkers isolated high-persistence (hip) mutants (77, 78) . They identified the first gene, hipA, to be known to contribute to persisters' formation; this gene was later identified as the toxin of a toxin-antitoxin (TA) module (79) . The hipA7 allele of the gene allowed mutated cells to form 1,000 times more persisters to ampicillin and increased persisters to other antibiotic classes such as fluoroquinolone and aminoglycosides (7, 80) . This was the first clue that persisters are multidrug tolerant. Importantly, the hipA7 mutant has the same MIC as the parent strain, indicating that the increased level of persisters is not due to acquisition of resistance.
Persisters as Dormant Cells
The hipA7 mutant was used for single-cell time-lapse microscopy which showed that persisters are slow-or nongrowing cells, stochastically formed and preexisting in the population (81) . This work could not be done with wild-type E. coli strains, because the number of persisters is very low. In a less direct observation, a wildtype E. coli culture was diluted several times and challenged with either ampicillin or ofloxacin. A gradual decline and eventual elimination of persisters was observed, despite keeping the initial population size constant (70) . In another investigation, the authors used an unstable green fluorescent protein variant expressed by a ribosomal promoter to distinguish between growing and nongrowing cells (82) . They demonstrated that nongrowing cells exist in an untreated E. coli population and that those cells are more tolerant to ofloxacin, a fluoroquinolone antibiotic capable of killing nongrowing cells. These results suggest that there is a population of persisters that are pre-existing in the population and are not formed in a response to the antibiotic treatment. However, later work demonstrated that persisters can also be formed as a response to an environmental stress such as DNA damage or oxidative stress (83, 84) .
The first transcriptome of persisters was generated by taking advantage of the fact that β-lactam antibiotics such as ampicillin are bacteriolytic, lysing the dying cells (7) . An E. coli culture was treated with a high concentration of ampicillin until only persisters survived. A simple centrifugation step was used to collect the persisters, and expression profiles were determined using a microarray. Several TA modules were among the genes overexpressed in persisters. Ectopic overexpression of RelE, the toxin of the relBA TA module, generated multidrug-tolerant cells, similarly to that observed with the hipA7 mutant. Based on these observations, it was suggested that stochastic variation in the expression of toxin genes generates dormant persister cells that are not killed by the antibiotic. Bactericidal antibiotics kill by binding to their target (such as ribosomes or DNA gyrase) and causing the production of corrupted toxic products (85) (86) (87) (88) (89) (90) . In dormant persisters the targets are inactive, so the cells survive (91) .
Genetic Determinants of Persisters
TA genes were first identified as addiction modules playing a role in plasmid maintenance (92) (93) (94) (95) . The toxin and antitoxin genes usually form an operon, with the antitoxin situated upstream of the toxin (96) . The antitoxin is less stable and is degraded by cellular proteases; if a daughter cell loses the plasmid, the antitoxin is rapidly degraded and the toxin stops the cells from growing. It was surprising to find homologues of TA genes on bacterial chromosomes, because their function there is not immediately clear (97) . A possible role in bacterial persistence was suggested when several of the known TAs in E. coli were found to be upregulated in the persisters' fraction (7, 82) . The bestknown persister gene, hipA of the hipBA operon, was suggested to be a TA module (98) ; more recent work has identified a novel mechanism of action. HipA is a kinase that phosphorylates elongation factor TU and halts protein synthesis (79) . The HipB antitoxin can neutralize HipA by binding to it and is regulated by the cellular protease Lon (99) (100) (101) (102) .
Although there were several clues suggesting a connection between TAs and persisters, a direct cause and effect was not established until recently. Single deletion of several of the TA modules did not result in reduction of persisters' levels. Gerdes and coworkers serially deleted up to 10 of the recognized type II TA modules (Δ10) in E. coli (103) . They found that at least five modules needed to be deleted before a significant reduction in persister levels was observed. When more TAs were deleted, a progressive reduction in persister levels was observed, up to about 2 logs in the Δ10 strain. These results clearly demonstrate a cause-and-effect relationship between TA modules and persisters in E. coli.
Several genome-wide approaches have been used to identify genetic determinants of persisters. A selection for the hip phenotype in an overexpression library identified glpD and plsB (104) . Both genes are involved in glycerol metabolism. Recent work has suggested a mechanism by which the glpD mutant has increased levels of methylglyoxal, a bacteriostatic metabolite (105) . Other screens have identified a number of regulators in both E. coli (106, 107) and P. aeruginosa (71, 108, 109) . No mutant has been identified in which no persisters are present. This suggests redundancy of the different mechanisms of persisters' formation. This view is consistent with recent work with S. aureus, where the authors suggested that persisters could be generated by many mechanisms, all of which result in a transient growth arrest (110) .
Persisters in M. tuberculosis
The current "short" course of antibiotic treatment for M. tuberculosis infections is 6 months long, despite the fact that the majority of the cells die in the first 2 weeks. Biphasic killing typical of persisters is easy to identify in the M. tuberculosis literature. They can be seen both in vitro and in vivo (6, (111) (112) (113) . Currently, very little is known about persisters in M. tuberculosis, and no persister genes have been identified to date. Recently, M. tuberculosis persisters were studied in vitro. The dynamics of persister cell formation were found to be similar to what was described for E. coli, P. aeruginosa, and S. aureus (6); the levels of persisters are low in lag and early log phase and then shoot up sharply in mid-log phase, reaching a high-level plateau in stationary state (Fig. 3B) . This indicates that a persister cell formation is stochastic early in the growth phase but has some deterministic component as the culture enters stationary phase (6, 114) .
The method used for isolating E. coli persisters was modified, and M. tuberculosis persisters were isolated by treating the bacterial population with D-cycloserine, a bacteriolytic antibiotic. A transcriptome of the isolated persisters was generated and analyzed. The most striking finding was the massive shutdown of expression: 282 genes were upregulated, while 1,408 were downregulated more than 2-fold. Many of the energy metabolism pathways were downregulated, indicating some level of dormancy (6) .
The M. tuberculosis genome has a large number of TA loci (97, 115, 116) . Their physiological roles are unknown, but some have been shown to be upregulated under stressful conditions and are suspected to be a part of the bacterial stress response (116). As discussed above, in E. coli, TA modules were identified as being involved in persister formation (103) . In the M. tuberculosis persisters' transcriptome, there were 10 TA modules that were upregulated (6) . Three M. tuberculosis RelE toxins were overexpressed, and the level of persisters was determined using four antibiotics (117) . Unlike E. coli, there was not a strong multidrug-tolerance phenotype. Each toxin increased tolerance for one drug specifically, with a very modest increase to some of the other drugs. These results could indicate that TAs in M. tuberculosis cannot generate multidrug tolerance or that only some unidentified TAs are capable of generating such tolerance. It is also possible that M. tuberculosis uses its large arsenal of TAs to generate many different populations, each with cells that overexpress one or more TAs and are specialized for survival under specific conditions.
As discussed earlier, the biofilm generated by many bacterial species is thought to contribute to the difficulty to cure, and the recalcitrant nature of, many infections. During M. tuberculosis infection, the immune response generates lesions called granulomas, where many of the bacilli reside (118) . Similar to a biofilm, the granulomas create a physical barrier between the residing bacteria and the immune system. Antibiotics kill sensitive cells in the granuloma, but the persisters survive and can repopulate when favorable conditions resume (Fig. 3C ). This scenario can explain the need for long treatment durations and the relapses common in M. tuberculosis infections.
INTERSECTION OF POPULATION-LEVEL AND SINGLE-CELL STUDIES
As described above, biofilm formation during infection appears to be a major cause of drug tolerance in many infections (119) . While this is often conceived of as population-level drug tolerance, it was also demonstrated that biofilms of P. aeruginosa harbor persister cells (72) . Lewis suggested a model explaining the recalcitrant nature of biofilm infection (120) . When a biofilm infection is treated with antibiotics, the majority of the bacterial cells die and only persisters survive. In the biofilm, persisters are protected from the immune system, and upon removal of the antibiotic pressure they can repopulate the biofilm culture. A similar role was recently suggested for the granuloma in M. tuberculosis infection: that it acts as a physical barrier protecting persisters from the immune system (6) .
We anticipate that in the future, there will be further convergence of population-level and single-cell studies. It is likely that the unique biology of specialized subpopulations of cells generated under specific conditions will contribute to biologically relevant outcomes in these settings. However, the mechanisms of drug tolerance will continue to reflect the importance of drug activation, growth rate, metabolic state, and permeability in dictating drug activity.
